Scholarlink

Background <p>The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year.</p> Results <p>This retrospective study included 52 RA patients. At baseline elderly patients had longer disease duration, more comorbidities and extraarticular involvement, and previously used conventional synthetic (cs) DMARDs (<i>p</i> &lt; 0.05). A statistically significant change from baseline was observed in the 6th and 12th months regarding Disease Activity Score (DAS-28) and the Health Assessment Questionnaire (HAQ) scores were observed in both groups following treatment with bDMARDs/tsDMARD (<i>p</i> &lt; 0.000). These changes in DAS-28 and HAQ scores were similar in both groups and showed no statistical difference between groups (<i>p</i> = 0.974 and <i>p</i> = 0.578 respectively).</p> <p>Also, no differences were observed between the groups with respect to the percentage of good, moderate or non-responders according to European Alliance of Associations for Rheumatology response criteria. Similarly, no differences were found between groups regarding severe adverse events, drug discontinuation or switch rates.</p> Conclusion <p>The efficacy and adverse effects of bDMARDs/tsDMARD were similar in elderly and younger RA patients. Both bDMARDs and tsDMARD are efficacious and safe for use in elderly RA patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月5日

查看全文
  • Yasemin Tombak,
  • Ajda Bal,
  • Emel Eksioglu,
  • Nihan Abidin,
  • Ozgur Zeliha Karaahmet,
  • Deniz Dulgeroglu

摘要

Background

The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year.

Results

This retrospective study included 52 RA patients. At baseline elderly patients had longer disease duration, more comorbidities and extraarticular involvement, and previously used conventional synthetic (cs) DMARDs (p < 0.05). A statistically significant change from baseline was observed in the 6th and 12th months regarding Disease Activity Score (DAS-28) and the Health Assessment Questionnaire (HAQ) scores were observed in both groups following treatment with bDMARDs/tsDMARD (p < 0.000). These changes in DAS-28 and HAQ scores were similar in both groups and showed no statistical difference between groups (p = 0.974 and p = 0.578 respectively).

Also, no differences were observed between the groups with respect to the percentage of good, moderate or non-responders according to European Alliance of Associations for Rheumatology response criteria. Similarly, no differences were found between groups regarding severe adverse events, drug discontinuation or switch rates.

Conclusion

The efficacy and adverse effects of bDMARDs/tsDMARD were similar in elderly and younger RA patients. Both bDMARDs and tsDMARD are efficacious and safe for use in elderly RA patients.